Mobile

A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002772-14

A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive control

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the efficacy of lumiracoxib in primary hip osteoarthritis by testing the hypotheses that lumiracoxib 100 mg o.d. is superior to placebo with respect to the pain sub-scale of the WOMAC 3.1LK questionnaire, the difficulty performing daily activities (DPDA) sub-scale of the WOMAC 3.1LK questionnaire, and patient's global assessment of disease activity on a 100 mm VAS after 13 weeks of treatment

Critère d'inclusion

  • Primary osteoarthritis of the hip

Liens